Treatment of Cancer with Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy; the IFOCUS Study
Latest Information Update: 09 Jan 2025
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms iFOCUS
Most Recent Events
- 07 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 28 Aug 2024 Status changed from not yet recruiting to recruiting.
- 06 Aug 2024 New trial record